Market Cap 1.61B
Revenue (ttm) 75.13M
Net Income (ttm) -146.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -194.88%
Debt to Equity Ratio 0.00
Volume 3,253,201
Avg Vol 7,323,486
Day's Range N/A - N/A
Shares Out 305.38M
Stochastic %K 5%
Beta 1.17
Analysts Strong Sell
Price Target $10.43

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a researc...

Industry: Biotechnology
Sector: Healthcare
Phone: 604 559 9005
Address:
150 W 4th Avenue, Vancouver, Canada
Stocktradesmoon
Stocktradesmoon Jun. 17 at 5:07 PM
$ABCL Today’s news is a game changer! Period.
0 · Reply
tradersunion353
tradersunion353 Jun. 17 at 4:50 PM
$ABCL Real investors here deserve 8 dollar by now and 20 after phase 2 data 10% bump on a news .. this is POS performance this stock gonna drop 20% next week whats the point?
1 · Reply
tkstockpicker
tkstockpicker Jun. 17 at 4:29 PM
$ABCL Stop set to protect huge gain again
1 · Reply
SultanK
SultanK Jun. 17 at 4:25 PM
$ABCL https://finance.yahoo.com/healthcare/articles/jazz-pharmaceuticals-abcellera-partner-antibody-125006964.html
0 · Reply
notreload_ai
notreload_ai Jun. 17 at 4:10 PM
$JAZZ and $ABCL enter a collaboration worth up to $876 million to develop next-generation T-cell engaging multispecific antibodies for GI cancers and solid tumors. https://notreload.xyz/xy/jazz-abcellera-sign-876m-deal-for-t-cell-engagers/
2 · Reply
TheDrunkTrader69
TheDrunkTrader69 Jun. 17 at 4:07 PM
0 · Reply
sir_sip_a_lot
sir_sip_a_lot Jun. 17 at 3:52 PM
$ABCL anyone know any more details to this? AbCellera Biologics (ABCL) shares rose 2.4%, and Jazz Pharmaceuticals (JAZZ) stock was up 1.6% premarket after the companies signed a preclinical research collaboration, option, and license deal to discover and develop T-cell-engaging multispecific antibodies.
3 · Reply
Ckkung71
Ckkung71 Jun. 17 at 3:38 PM
$ABCL Will we see new price targets soon?
1 · Reply
MorganHoratio
MorganHoratio Jun. 17 at 2:41 PM
10 Risk/Reward Setups I’m Watching Right Now $QS $ABCL $HIVE $FABC $SOUN Disruptor $FABC (Fabric.AI) delivered an epic milestone on May 18, locking down NDAs with two leading mega-chipmakers for its Neural I/o™ platform designed to solve AI data-center bottlenecks ahead of its late-2026 demonstration. Concurrently, $HIVE continues to upscale its high-density megawatt footprint into premium AI/HPC hosting. Next-gen battery pioneer $QS is stabilizing on its structural right-side base following extensive Tier-1 validation, while conversational voice leader $SOUN recalibrates for broad edge-AI monetization. This transient macro compression resets these high-velocity assets perfectly into vital Fibonacci technical support. Are you exploiting this dip to accumulate the newly de-risked, NDA-backed technical catalyst play inside $FABC, or backing the deeply washed-out valuation moat of solid-state giant $QS for the ultimate turnaround?
0 · Reply
PaloPB
PaloPB Jun. 17 at 2:32 PM
$ABCL can you imagine that ABCL goes similar trajectory as Regeneron did with their success story of Aflibercept?
0 · Reply
Latest News on ABCL
AbCellera appoints Victor Sandor to board of directors

2026-06-05T13:05:56.000Z - 12 days ago

AbCellera appoints Victor Sandor to board of directors


AbCellera price target raised to $8 from $7 at Stifel

2026-05-12T10:58:11.000Z - 5 weeks ago

AbCellera price target raised to $8 from $7 at Stifel


AbCellera Biologics Earnings Call Transcript: Q1 2026

May 11, 2026, 5:00 PM EDT - 5 weeks ago

AbCellera Biologics Earnings Call Transcript: Q1 2026


AbCellera Biologics Earnings release: Q1 2026

May 11, 2026, 5:00 PM EDT - 5 weeks ago

AbCellera Biologics Earnings release: Q1 2026


AbCellera Biologics Quarterly report: Q1 2026

May 11, 2026, 5:00 PM EDT - 5 weeks ago

AbCellera Biologics Quarterly report: Q1 2026


AbCellera Biologics Slides: Q1 2026

May 11, 2026, 5:00 PM EDT - 5 weeks ago

AbCellera Biologics Slides: Q1 2026


AbCellera initiated with an Overweight at Cantor Fitzgerald

2026-05-05T10:36:31.000Z - 6 weeks ago

AbCellera initiated with an Overweight at Cantor Fitzgerald


AbCellera Biologics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 7 weeks ago

AbCellera Biologics Proxy statement: Proxy filing


AbCellera Biologics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 7 weeks ago

AbCellera Biologics Proxy statement: Proxy filing


AbCellera initiated with a Buy at JonesResearch

2026-04-09T20:10:26.000Z - 2 months ago

AbCellera initiated with a Buy at JonesResearch


AbCellera Biologics Earnings Call Transcript: Q4 2025

Feb 24, 2026, 5:00 PM EST - 4 months ago

AbCellera Biologics Earnings Call Transcript: Q4 2025


AbCellera Biologics Annual report: Q4 2025

Feb 24, 2026, 5:00 PM EST - 4 months ago

AbCellera Biologics Annual report: Q4 2025


AbCellera Biologics Earnings release: Q4 2025

Feb 24, 2026, 5:00 PM EST - 4 months ago

AbCellera Biologics Earnings release: Q4 2025


AbCellera Biologics Slides: Q4 2025

Feb 24, 2026, 5:00 PM EST - 4 months ago

AbCellera Biologics Slides: Q4 2025


AbCellera reports FY25 EPS (49c) vs. (55c) last year

2026-02-24T21:15:21.000Z - 4 months ago

AbCellera reports FY25 EPS (49c) vs. (55c) last year


AbCellera Reports Full Year 2025 Business Results

Feb 24, 2026, 4:05 PM EST - 4 months ago

AbCellera Reports Full Year 2025 Business Results


AbCellera Biologics Slides: Corporate presentation

Jan 14, 2026, 7:00 AM EST - 5 months ago

AbCellera Biologics Slides: Corporate presentation


AbCellera Appoints Dr. Stephen Quake to its Board of Directors

Nov 10, 2025, 9:00 AM EST - 7 months ago

AbCellera Appoints Dr. Stephen Quake to its Board of Directors


AbCellera Biologics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 5:00 PM EST - 7 months ago

AbCellera Biologics Earnings Call Transcript: Q3 2025


AbCellera Biologics Quarterly report: Q3 2025

Nov 6, 2025, 5:00 PM EST - 7 months ago

AbCellera Biologics Quarterly report: Q3 2025


AbCellera Biologics Earnings release: Q3 2025

Nov 6, 2025, 5:00 PM EST - 7 months ago

AbCellera Biologics Earnings release: Q3 2025


AbCellera Biologics Slides: Q3 2025

Nov 6, 2025, 5:00 PM EST - 7 months ago

AbCellera Biologics Slides: Q3 2025


AbCellera Reports Q3 2025 Business Results

Nov 6, 2025, 4:05 PM EST - 7 months ago

AbCellera Reports Q3 2025 Business Results


AbCellera appoints Sarah Noonberg as Chief Medical Officer

2025-09-10T13:20:54.000Z - 10 months ago

AbCellera appoints Sarah Noonberg as Chief Medical Officer

MGX


AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

Sep 10, 2025, 9:07 AM EDT - 10 months ago

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer


AbCellera doses first participants in Phase 1 trial of ABCL575

2025-08-27T13:20:26.000Z - 10 months ago

AbCellera doses first participants in Phase 1 trial of ABCL575


AbCellera Biologics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 11 months ago

AbCellera Biologics Earnings Call Transcript: Q2 2025


AbCellera Biologics Quarterly report: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 11 months ago

AbCellera Biologics Quarterly report: Q2 2025


AbCellera Biologics Earnings release: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 11 months ago

AbCellera Biologics Earnings release: Q2 2025


AbCellera Biologics Slides: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 11 months ago

AbCellera Biologics Slides: Q2 2025


AbCellera Biologics Slides: Corporate Presentation

Aug 1, 2025, 7:00 AM EDT - 11 months ago

AbCellera Biologics Slides: Corporate Presentation


AbCellera Biologics Earnings Call Transcript: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q1 2025


AbCellera Biologics Earnings release: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings release: Q1 2025


AbCellera Biologics Quarterly report: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Quarterly report: Q1 2025


AbCellera Biologics Slides: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Slides: Q1 2025


AbCellera Reports Q1 2025 Business Results

May 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera Reports Q1 2025 Business Results


AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AbCellera Biologics Proxy statement: Proxy Filing


AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AbCellera Biologics Proxy statement: Proxy Filing


AbCellera Biologics Earnings Call Transcript: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q4 2024


AbCellera Biologics Earnings release: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings release: Q4 2024


AbCellera Biologics Annual report: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Annual report: Q4 2024


AbCellera Biologics Slides: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Slides: Q4 2024


AbCellera Reports Full Year 2024 Business Results

Feb 27, 2025, 4:05 PM EST - 1 year ago

AbCellera Reports Full Year 2024 Business Results


AbCellera Biologics Slides: FY 2025

Jan 15, 2025, 7:30 PM EST - 1 year ago

AbCellera Biologics Slides: FY 2025


AbCellera Biologics Earnings Call Transcript: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q3 2024


AbCellera Biologics Quarterly report: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Quarterly report: Q3 2024


AbCellera Biologics Earnings release: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings release: Q3 2024


AbCellera Biologics Slides: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Slides: Q3 2024


AbCellera Reports Q3 2024 Business Results

Nov 4, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Q3 2024 Business Results


AbCellera Biologics Earnings Call Transcript: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings Call Transcript: Q2 2024


AbCellera Biologics Quarterly report: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Quarterly report: Q2 2024


AbCellera Biologics Earnings release: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings release: Q2 2024


AbCellera Biologics Slides: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Slides: Q2 2024


AbCellera Reports Q2 2024 Business Results

Aug 6, 2024, 4:05 PM EDT - 2 years ago

AbCellera Reports Q2 2024 Business Results


AbCellera Biologics Earnings Call Transcript: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings Call Transcript: Q1 2024


AbCellera Biologics Quarterly report: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Quarterly report: Q1 2024


AbCellera Biologics Earnings release: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings release: Q1 2024


AbCellera Biologics Slides: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Slides: Q1 2024


AbCellera Reports Q1 2024 Business Results

May 7, 2024, 4:05 PM EDT - 2 years ago

AbCellera Reports Q1 2024 Business Results


AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

AbCellera Biologics Proxy statement: Proxy Filing


AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

AbCellera Biologics Proxy statement: Proxy Filing


Stocktradesmoon
Stocktradesmoon Jun. 17 at 5:07 PM
$ABCL Today’s news is a game changer! Period.
0 · Reply
tradersunion353
tradersunion353 Jun. 17 at 4:50 PM
$ABCL Real investors here deserve 8 dollar by now and 20 after phase 2 data 10% bump on a news .. this is POS performance this stock gonna drop 20% next week whats the point?
1 · Reply
tkstockpicker
tkstockpicker Jun. 17 at 4:29 PM
$ABCL Stop set to protect huge gain again
1 · Reply
SultanK
SultanK Jun. 17 at 4:25 PM
$ABCL https://finance.yahoo.com/healthcare/articles/jazz-pharmaceuticals-abcellera-partner-antibody-125006964.html
0 · Reply
notreload_ai
notreload_ai Jun. 17 at 4:10 PM
$JAZZ and $ABCL enter a collaboration worth up to $876 million to develop next-generation T-cell engaging multispecific antibodies for GI cancers and solid tumors. https://notreload.xyz/xy/jazz-abcellera-sign-876m-deal-for-t-cell-engagers/
2 · Reply
TheDrunkTrader69
TheDrunkTrader69 Jun. 17 at 4:07 PM
0 · Reply
sir_sip_a_lot
sir_sip_a_lot Jun. 17 at 3:52 PM
$ABCL anyone know any more details to this? AbCellera Biologics (ABCL) shares rose 2.4%, and Jazz Pharmaceuticals (JAZZ) stock was up 1.6% premarket after the companies signed a preclinical research collaboration, option, and license deal to discover and develop T-cell-engaging multispecific antibodies.
3 · Reply
Ckkung71
Ckkung71 Jun. 17 at 3:38 PM
$ABCL Will we see new price targets soon?
1 · Reply
MorganHoratio
MorganHoratio Jun. 17 at 2:41 PM
10 Risk/Reward Setups I’m Watching Right Now $QS $ABCL $HIVE $FABC $SOUN Disruptor $FABC (Fabric.AI) delivered an epic milestone on May 18, locking down NDAs with two leading mega-chipmakers for its Neural I/o™ platform designed to solve AI data-center bottlenecks ahead of its late-2026 demonstration. Concurrently, $HIVE continues to upscale its high-density megawatt footprint into premium AI/HPC hosting. Next-gen battery pioneer $QS is stabilizing on its structural right-side base following extensive Tier-1 validation, while conversational voice leader $SOUN recalibrates for broad edge-AI monetization. This transient macro compression resets these high-velocity assets perfectly into vital Fibonacci technical support. Are you exploiting this dip to accumulate the newly de-risked, NDA-backed technical catalyst play inside $FABC, or backing the deeply washed-out valuation moat of solid-state giant $QS for the ultimate turnaround?
0 · Reply
PaloPB
PaloPB Jun. 17 at 2:32 PM
$ABCL can you imagine that ABCL goes similar trajectory as Regeneron did with their success story of Aflibercept?
0 · Reply
tradersunion353
tradersunion353 Jun. 17 at 2:23 PM
$ABCL Overhyped junk is down for 5 years 45 dollars.. it can hardly move 30 cents on any news Paid artist and demamp clown are already getting high here.. No real investor feel happy for parking their money for no returns,
0 · Reply
tkstockpicker
tkstockpicker Jun. 17 at 1:54 PM
$ABCL Yep going to get paid yet again
0 · Reply
Buying_Low_Selling_High
Buying_Low_Selling_High Jun. 17 at 1:52 PM
$ABCL So under the radar for most. These upfront payments probably fully fund ABCL635 clinical trials and extends the cash runway till 2030 (possibly even making ABCL profitable very soon). This validates the discovery platform once again and reduces the long term risks significantly. Massive positive news in my opinion.
1 · Reply
JennyRowes
JennyRowes Jun. 17 at 1:13 PM
0 · Reply
JennyRowes
JennyRowes Jun. 17 at 1:10 PM
$ABCL from shareholder letter…
0 · Reply
Merlintrader
Merlintrader Jun. 17 at 1:04 PM
$JAZZ Jazz Pharmaceuticals + AbCellera ($JAZZ $ABCL): T-Cell Engager Partnership and Competitive Oncology Landscape https://www.merlintrader.com/jazz-pharmaceuticals-abcellera-partnership/
0 · Reply
bonecrack_benny
bonecrack_benny Jun. 17 at 1:00 PM
$ABCL Jazz me, baby. Carl, text me when you see this, honey.
0 · Reply
DeMampCamp
DeMampCamp Jun. 17 at 12:57 PM
$ABCL Great news this morning! Don't forget, the FED rate decision is today, could be volatile! Cheers all and happy Hump Day!
0 · Reply
tradersunion353
tradersunion353 Jun. 17 at 12:56 PM
$ABCL overhyped company primarily pumped by paid pumpers will close red be careful playing with phase 2 data i am a shareholder for last few years almost every time this shady company disappoints retail investors dont fall for any demamp clown and others
0 · Reply
JennyRowes
JennyRowes Jun. 17 at 12:29 PM
$ABCL wow, this news comes out of nowhere….. Jazz deal release of new partnership with 3 (not 2) programs, at $ 28M each, for a total of $ 84 M “upfront“, snd $ 700+ M each in potential milestones. TCE platform is the focus. Nothing to do with ABCL635. ABCL is more than people can see
0 · Reply
FreyBentos
FreyBentos Jun. 17 at 12:22 PM
$ABCL Don't think I've ever seen this thing trending in 5 years of holding lol
1 · Reply
TheDrunkTrader69
TheDrunkTrader69 Jun. 17 at 12:07 PM
0 · Reply